Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

XSEC:300760 Stock Report

Market Cap: CN¥299.7b

Shenzhen Mindray Bio-Medical Electronics Valuation

Is 300760 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300760 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300760 (CN¥247.85) is trading below our estimate of fair value (CN¥429.55)

Significantly Below Fair Value: 300760 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300760?

Key metric: As 300760 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300760. This is calculated by dividing 300760's market cap by their current earnings.
What is 300760's PE Ratio?
PE Ratio24.2x
EarningsCN¥12.38b
Market CapCN¥299.75b

Price to Earnings Ratio vs Peers

How does 300760's PE Ratio compare to its peers?

The above table shows the PE ratio for 300760 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average70.3x
688271 Shanghai United Imaging Healthcare
65.3x31.0%CN¥103.3b
002223 Jiangsu Yuyue Medical Equipment & Supply
20.6x18.7%CN¥35.8b
688617 APT Medical
53.5x28.8%CN¥35.3b
688198 Beijing Balance Medical TechnologyLtd
142x41.1%CN¥14.7b
300760 Shenzhen Mindray Bio-Medical Electronics
24.2x13.3%CN¥299.7b

Price-To-Earnings vs Peers: 300760 is good value based on its Price-To-Earnings Ratio (24.2x) compared to the peer average (70.3x).

Price to Earnings Ratio vs Industry

How does 300760's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300760 24.2xIndustry Avg. 31.6xNo. of Companies15PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300760 is good value based on its Price-To-Earnings Ratio (24.2x) compared to the CN Medical Equipment industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is 300760's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300760 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.2x
Fair PE Ratio31.9x

Price-To-Earnings vs Fair Ratio: 300760 is good value based on its Price-To-Earnings Ratio (24.2x) compared to the estimated Fair Price-To-Earnings Ratio (31.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300760 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥247.85
CN¥349.64
+41.1%
9.9%CN¥418.21CN¥280.00n/a21
Dec ’25CN¥260.49
CN¥352.78
+35.4%
9.8%CN¥418.21CN¥280.00n/a21
Nov ’25CN¥266.25
CN¥357.36
+34.2%
9.3%CN¥418.21CN¥280.00n/a22
Oct ’25CN¥293.00
CN¥363.48
+24.1%
10.1%CN¥430.00CN¥280.00n/a21
Sep ’25CN¥250.80
CN¥379.98
+51.5%
9.4%CN¥450.00CN¥310.00n/a20
Aug ’25CN¥255.23
CN¥390.68
+53.1%
8.3%CN¥450.00CN¥323.68n/a20
Jul ’25CN¥285.03
CN¥393.30
+38.0%
8.8%CN¥460.00CN¥323.68n/a18
Jun ’25CN¥290.14
CN¥393.76
+35.7%
8.5%CN¥460.00CN¥323.68n/a19
May ’25CN¥304.59
CN¥394.25
+29.4%
8.7%CN¥450.00CN¥325.00n/a19
Apr ’25CN¥282.75
CN¥396.61
+40.3%
9.0%CN¥452.99CN¥333.48n/a19
Mar ’25CN¥290.17
CN¥396.99
+36.8%
9.4%CN¥470.00CN¥333.48n/a19
Feb ’25CN¥273.19
CN¥396.99
+45.3%
9.4%CN¥470.00CN¥333.48n/a19
Jan ’25CN¥290.60
CN¥395.95
+36.3%
10.7%CN¥470.00CN¥320.00CN¥255.0019
Dec ’24CN¥290.10
CN¥396.55
+36.7%
10.4%CN¥470.00CN¥320.00CN¥260.4919
Nov ’24CN¥282.80
CN¥397.47
+40.5%
10.4%CN¥470.00CN¥320.00CN¥266.2519
Oct ’24CN¥269.81
CN¥400.79
+48.5%
11.1%CN¥476.95CN¥320.00CN¥293.0019
Sep ’24CN¥269.30
CN¥408.50
+51.7%
11.3%CN¥481.92CN¥320.00CN¥250.8019
Aug ’24CN¥295.24
CN¥439.65
+48.9%
10.1%CN¥552.20CN¥372.26CN¥255.2319
Jul ’24CN¥299.80
CN¥439.65
+46.6%
10.1%CN¥552.20CN¥372.26CN¥285.0319
Jun ’24CN¥299.04
CN¥439.65
+47.0%
10.1%CN¥552.20CN¥372.26CN¥290.1419
May ’24CN¥311.90
CN¥435.97
+39.8%
8.0%CN¥520.00CN¥375.05CN¥304.5917
Apr ’24CN¥311.71
CN¥446.60
+43.3%
9.8%CN¥565.43CN¥385.33CN¥282.7516
Mar ’24CN¥316.49
CN¥444.77
+40.5%
10.3%CN¥565.43CN¥380.95CN¥290.1716
Feb ’24CN¥330.99
CN¥444.77
+34.4%
10.3%CN¥565.43CN¥380.95CN¥273.1916
Jan ’24CN¥315.97
CN¥440.33
+39.4%
14.2%CN¥600.00CN¥350.00CN¥290.6016

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:45
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is covered by 52 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sandra SunBofA Global Research
Zhishun SiuCCB International Securities Limited
Yue GaoChangjiang Securities Co. LTD.